Damian G. O.

Engages in translational research across major solid cancers, emphasizing molecularly defined subgroups such as Non‑small cell lung cancer, Breast cancer, Colorectal cancer, Pancreatic ductal adenocarcinoma, Gastric cancer, Ovarian cancer, Head and neck squamous cell carcinoma, Renal cell carcinoma and Prostate cancer.

• Non‑small cell lung cancer with KRAS or EGFR alterations
• Breast cancer subtypes including HER2‑low and hormone‑receptor positive disease
• Colorectal cancer with microsatellite instability or KRAS mutations
• Pancreatic ductal adenocarcinoma refractory to standard chemotherapy
• Head and neck squamous cell carcinoma resistant to conventional therapy

Focus on biomarker‑driven therapies and combination regimens for advanced solid malignancies.

Specializes in kidney and urinary tract cancers, integrating surgical innovation with systemic treatment for entities such as Renal cell carcinoma, Urothelial carcinoma, Upper tract urothelial carcinoma and Bladder cancer.

• Renal cell carcinoma including clear‑cell and non‑clear‑cell variants
• Urothelial carcinoma of the bladder and upper urinary tract
• Upper tract urothelial carcinoma with neoadjuvant approaches
• Bladder cancer refractory to intravesical therapy
• Renal preservation strategies in chronic kidney disease

Investigates neoadjuvant and adjuvant strategies to improve survival in renal and urothelial malignancies.

Addresses acute and chronic heart and lung conditions, including severe syndromes such as Acute respiratory distress syndrome, Acute heart failure, Chronic obstructive pulmonary disease, Asthma and Myocardial infarction.

• Acute respiratory distress syndrome management in critical care
• Acute heart failure with measurable residual dysfunction
• Chronic obstructive pulmonary disease phenotyping and therapy
• Asthma severe eosinophilic phenotype
• Myocardial infarction secondary prevention strategies

Therapeutic focus includes novel anti‑inflammatory and hemodynamic agents for severe cardiopulmonary disease.

Explores immune‑mediated diseases affecting skin, joints and mucosal surfaces, such as Hidradenitis suppurativa, Cutaneous lupus erythematosus, Inflammatory bowel disease (Crohn’s disease), Multiple sclerosis, Rheumatoid arthritis and Chronic rhinosinusitis with nasal polyps.

• Hidradenitis suppurativa with biologic intervention
• Cutaneous lupus erythematosus targeted therapy
• Inflammatory bowel disease (Crohn’s disease) refractory to standard treatment
• Multiple sclerosis relapse‑prevention strategies
• Rheumatoid arthritis difficult‑to‑treat phenotype

Seeks to modulate dysregulated immune pathways using biologics and small molecules.